The primary Varicella Zoster Virus (VZV) infection results in varicella, a generally benign, self-limiting disease in immunocompetent children. Despite the usual course a possible fatal evolution of the primary infection is observed predominantly in immunocompromised subjects and in adults, especially emigrating from tropical regions. Two cases of fatal varicella have been investigated and discussed. Death occurred in two patients over 40 years of age, coming from South Asia and receiving chronic immunosuppressive therapy. The forensic expert must be cautious and consider all clinical records in managing fatal varicella cases, bearing in mind risk factors and pre-existing conditions such as age, geographical provenance and pathological comorbidity, which may lead to a bad prognosis irrespective of therapies. Based on the severe and fatal course observed in the reported cases, an extension of the immunization program appears advisable for immigrants from tropical countries, especially before scheduled immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.legalmed.2018.03.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fatal disseminated varicella infection in a patient on long-term oral corticosteroids.
Am J Emerg Med
December 2024
Department of Critical Care Medicine, Shenzhen Baoan Clinical Medical College of Guangdong Medical University,118 Longjinger Road, Baoan District, Shenzhen, Guangdong 518101, China; Department of Critical Care Medicine, The Second Affiliated Hospital of Shenzhen University, 118 Longjinger Road, Baoan District, Shenzhen, Guangdong 518101, China. Electronic address:
Primary varicella-zoster virus (VZV) infection typically occurs in childhood and is generally mild. However, in immunocompromised patients, VZV-related diseases can be more severe. Fatal cases of disseminated varicella are still rare.
View Article and Find Full Text PDFA Booster Administration of the OKA/SK Strain Causes Fatal Disseminated Varicella in an Immunocompetent Child.
J Med Virol
January 2025
Division of Immunization Services, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
Cerebral Hemorrhage in Varicella-Zoster Virus Encephalitis: A Case Study.
Am J Case Rep
January 2025
Department of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
BACKGROUND Varicella-zoster virus (VZV) encephalitis is a commonly reported form of encephalitis that clinically manifests as skin lesions, fever, headache, and neuropsychiatric symptoms. We present a case of a patient with VZV encephalitis complicated by cerebral hemorrhagic transformation, characterized by high levels of inflammation and protein in the cerebrospinal fluid. The aim is to highlight the risk of hemorrhagic transformation associated with VZV encephalitis.
View Article and Find Full Text PDFCurrent epidemiology of infectious encephalitis: a narrative review.
Clin Microbiol Infect
December 2024
Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; European Society of Clinical Microbiology and Infectious Diseases Study Group of Infections of the Brain (ESGIB), Basel, Switzerland.
Background: Infectious encephalitis poses a global health challenge with high mortality and severe neurological consequences in survivors. Emerging pathogens and outbreaks are reshaping the patterns of the disease.
Objectives: The objective of this study is to understand the current epidemiology for improving prevention, diagnosis, and treatment.
A prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the recombinant zoster vaccine in Chinese adults ≥50 years of age.
Hum Vaccin Immunother
December 2024
GSK, Rockville, USA.
This post-marketing surveillance study evaluated the safety of the adjuvanted recombinant zoster vaccine (RZV) in Chinese adults, given the limited country-specific safety data accumulated since the 2019 licensure of RZV in China for adults ≥ 50 years of age (YOA). This descriptive, prospective cohort study enrolled adults ≥ 50 YOA who voluntarily received RZV per routine clinical practice in six centers in China. The primary outcomes were occurrence, intensity, and causal relationship to vaccination of medically attended adverse events (MAEs) within 30 days post-any dose.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!